A combination of public and private entities have banded together to form a loosely organized investment consortium that will focus on early stage biotech enterprises in China. The Biotech Science and Technology Venture Alliance combines 22 partners, some from industry, others from academia. Total funding is expected to reach $145 million, but each member of the alliance can decide how to invest its own money, which makes the alliance different from a typical venture capital fund. More details...